VolitionRX (NYSEAMERICAN:VNRX) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.81 and traded as low as $1.1550. VolitionRX shares last traded at $1.16, with a volume of 124,738 shares.

Analyst Upgrades and Downgrades

Several analysts have weighed in on VNRX shares. Maxim Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of VolitionRX in a research report on Thursday, June 18th. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. HC Wainwright lowered their target price on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Benchmark restated a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. Finally, Citigroup lowered VolitionRX to a “hold” rating in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, VolitionRX has a consensus rating of “Hold” and an average price target of $28.00.

VolitionRX Stock Down 5.2%

The company has a fifty day simple moving average of $1.79 and a 200 day simple moving average of $3.44. The firm has a market capitalization of $9.49 million, a P/E ratio of -0.26 and a beta of 1.12.

VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings results on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The firm had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.52 million. As a group, equities analysts expect that VolitionRX Limited will post -2.4 earnings per share for the current fiscal year.

Institutional Trading of VolitionRX

A number of institutional investors and hedge funds have recently bought and sold shares of VNRX. Virtu Financial LLC purchased a new stake in shares of VolitionRX during the third quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in VolitionRX in the 2nd quarter worth approximately $52,000. Geode Capital Management LLC lifted its position in VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 85,816 shares in the last quarter. Jane Street Group LLC bought a new position in VolitionRX in the 4th quarter valued at approximately $28,000. Finally, Squarepoint Ops LLC purchased a new stake in VolitionRX during the 4th quarter valued at $34,000. 8.09% of the stock is currently owned by institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.